EGFR and lung adenocarcinoma: In the study titled “First Line IRESSA Versus Carboplatin/Paclitaxel in Asia (IPASS)” in East Asia in which only a selected population of nonsmokers with adenocarcinoma of the lung were included, EGFR mutations were present in 59.7%.14 In our study, the most common sites of EGFR mutation were deletion in exon 19 and mutation at exon 21 (L858R).